Hoth Therapeutics Files 8-K

Ticker: HOTH · Form: 8-K · Filed: 2025-10-17T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-filing

Related Tickers: HOTH

TL;DR

HOTH filed an 8-K on 10/17/25, check for updates.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on October 17, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or details about the nature of the events reported.

Why It Matters

This filing indicates that Hoth Therapeutics has made a regulatory submission to the SEC, which may contain updates on company events or financial status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose specific material information that would immediately impact risk.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Hoth Therapeutics in this 8-K filing?

The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported, only that this item is being addressed.

When was this 8-K filing submitted to the SEC?

The filing was submitted on October 17, 2025.

What is Hoth Therapeutics, Inc.'s state of incorporation?

Hoth Therapeutics, Inc. is incorporated in Nevada.

What is the principal executive office address for Hoth Therapeutics, Inc.?

The principal executive office is located at 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.

Does this filing include specific financial statements or exhibits?

The filing indicates 'Financial Statements and Exhibits' as an item information, but the specific content of these is not detailed in the provided text.

From the Filing

0001213900-25-099969.txt : 20251017 0001213900-25-099969.hdr.sgml : 20251017 20251017161534 ACCESSION NUMBER: 0001213900-25-099969 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20251017 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251017 DATE AS OF CHANGE: 20251017 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 251401021 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR SUITE 5066 CITY: NEW YORK STATE: NY ZIP: 10036 8-K 1 ea0261354-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2025-10-17 2025-10-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) October 17, 2025   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   1177 Avenue of the Americas , 5th Floor , Suite 5066 New York , NY 10036 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 8.01 Other Events.   Hoth Therapeutics, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after October 17, 2025, in presentations about the Company’s operations and performance. The Presentation Materials are filed as Exhibit 99.1 to this Current Report on Form 8-K.   The information contained in the Presentation Materials is summary information that should be considered within the context of the Co

View on Read The Filing